. Author manuscript; available in PMC: 2013 Nov 1.

Published in final edited form as: Ophthalmology. 2012 Jul 13;119(11):2377–2385. doi: 10.1016/j.ophtha.2012.05.032

Table 6. Hazard ratio for Intraocular Pressure <8mmHg, sustained for at least 30 days.

			Univariate n=6785 events=241			Multivariate^** n=6524 events=189
			Events/ At Risk	Hazard Ratio (95% Confidence Interval)	p- value	Events/ At Risk	Hazard Ratio (95% Confidence Interval)	p- value
Age	<18		79/973	3.49 (2.22 - 5.51)	<.001	58/924	1.74 (0.95 - 3.18)	0.35
	18-25		43/897	2.01 (1.21 - 3.33)		36/876	1.61 (0.90 - 2.88)
	26-35		37/1483	Reference		31/1455	Reference
	36-45		31/1300	1.01 (0.58 - 1.76)		25/1273	1.02 (0.57 - 1.84)
	46-55		25/983	1.06 (0.61 - 1.85)		20/963	1.11 (0.57 - 2.16)
	56-65		10/556	0.78 (0.33 - 1.85)		9/548	0.74 (0.29 - 1.90)
	>65		12/497	1.23 (0.60 - 2.49)		10/485	0.79 (0.32 - 1.97)
Gender	Male		66/2388	Reference	0.03	48/2299	Reference	0.41
Gender	Female		175/4397	1.42 (1.03 - 1.97)	0.03	141/4225	1.17 (0.81 - 1.70)	0.41
Race	White		137/4755	Reference	<.001	112/4624	Reference	0.06
	African-derived		82/1208	2.35 (1.70 - 3.26)		60/1139	1.56 (1.03 - 2.36)
	Other		22/822	1.10 (0.65 - 1.85)		17/761	0.89 (0.51 - 1.54)
Contralateral uveitis	No		18/1170	Reference	0.005	16/1142	Reference	0.28
Contralateral uveitis	Yes		223/5615	2.01 (1.24 - 3.28)	0.005	173/5382	1.35 (0.78 - 2.31)	0.28
Hypertension	No		183/5547	Reference	0.17	147/5336	Reference	0.47
Hypertension	Yes		58/1238	1.29 (0.90 - 1.84)	0.17	42/1188	1.20 (0.73 - 1.98)	0.47
Diabetes	No		228/6398	Reference	0.63	180/6153	Reference	0.69
Diabetes	Yes		13/387	0.86 (0.48 - 1.56)	0.63	9/371	0.86 (0.42 - 1.78)	0.69
Systemic Diseases	Any^†		100/1846	1.59 (1.17 - 2.15)	0.003	71/1764	0.73 (0.48 - 1.13)	0.16
	HLA-B27 and/or spondyloarthropathy		24/801	0.79 (0.50 - 1.24)	0.3	19/783	1.35 (0.71 - 2.56)	0.36
	Juvenile idopathic arthritis		57/329	5.59 (3.91 - 7.98)	<.001	37/288	3.09 (1.56 - 6.14)	0.001
	Sarcoidosis		26/576	1.06 (0.66 - 1.69)	0.82	20/553	1.25 (0.60 - 2.57)	0.55
Type of Uveitis	Anterior Uveitis		124/3609	Reference	<.001	97/3448	Reference	0.02
	Intermediate Uveitis		25/1197	0.51 (0.30 - 0.85)		22/1168	0.72 (0.40 - 1.28)
	Posterior Uveitis		19/1112	0.39 (0.23 - 0.68)		16/1086	0.67 (0.36 - 1.27)
	Panuveitis		73/867	2.01 (1.42 - 2.83)		54/822	1.61 (1.01 - 2.58)
Duration of uveitis at presentation	<6 months		55/2749	Reference	<.001	41/2610	Reference	0.03
	6 months to 2 years		34/1401	1.10 (0.66 - 1.83)		28/1378	0.87 (0.50 - 1.50)
	2 to 5 years		43/1134	1.76 (1.10 - 2.82)		40/1110	1.59 (0.94 - 2.70)
	Greater than 5 years		109/1501	3.42 (2.33 - 5.00)		80/1426	1.70 (1.05 - 2.74)
Prior Cataract Surgery by Type	None		94/^*	Reference	<.001	65/^*	Reference	<.001
	Phaco		25/^*	2.97 (1.81 - 4.89)		21/^*	2.78 (1.62 - 4.79)
	Extracapsular cataract extraction		36/^*	6.58 (4.31 - 10.04)		34/^*	5.47 (3.35 - 8.92)
	Intracapsular cataract extraction		15/^*	11.82 (5.74 - 24.35)		12/^*	7.03 (2.84 - 17.40)
	Pars plana lensectomy		26/^*	14.54 (9.15 - 23.11)		25/^*	5.49 (2.79 - 10.82)
	Unknown		45/^*	6.42 (4.26 - 9.70)		32/^*	3.79 (2.20 - 6.53)
Prior Pars Plana Vitrectomy	No		182/^*	Reference	<.001	137/^*	Reference	0.008
Prior Pars Plana Vitrectomy	Yes		59/^*	4.76 (3.37 - 6.73)	<.001	52/^*	1.89 (1.24 - 2.90)	0.008
Prior Retinal Detachment Surgery	No		231/^*	Reference	<.001	181/^*	Reference	0.52
Prior Retinal Detachment Surgery	Yes		10/^*	3.26 (1.65 - 6.45)	<.001	8/^*	0.73 (0.29 - 1.88)	0.52
Signs of Inflammatory Activity	Anterior chamber cells	Quiet	128/^*	Reference	<.001	101/^*	Reference	0.06
		0.5+	47/^*	1.92 (1.35 - 2.74)		38/^*	1.06 (0.68 - 1.66)
		1+	23/^*	1.64 (1.01 - 2.66)		20/^*	1.20 (0.72 - 1.99)
		2+	19/^*	2.07 (1.24 - 3.45)		15/^*	1.42 (0.80 - 2.52)
		3+ or worse	18/^*	3.73 (2.24 - 6.19)		15/^*	2.57 (1.34 - 4.91)
	Vitreous cells	Quiet	132/^*	Reference	0.004	114/^*	Reference	0.04
		0.5+	28/^*	1.43 (0.92 - 2.24)		26/^*	1.25 (0.77 - 2.02)
		1+	22/^*	1.18 (0.73 - 1.90)		21/^*	1.20 (0.71 - 2.03)
		2+	14/^*	1.35 (0.76 - 2.38)		14/^*	1.55 (0.81 - 2.95)
		3+ or worse	11/^*	3.73 (1.90 - 7.31)		8/^*	2.98 (1.49 - 5.95)
	Vitreous haze	Quiet	155/^*	Reference	<.001	137/^*	Reference	0.006
		1+	32/^*	2.31 (1.51 - 3.52)		31/^*	1.97 (1.23 - 3.15)
		2+	12/^*	3.30 (1.75 - 6.23)		11/^*	2.46 (1.24 - 4.90)
		3+ or worse	7/^*	4.38 (1.86 - 10.31)		5/^*	1.60 (0.65 - 3.95)
	Keratic precipitates	No	198/^*	Reference	0.03	156/^*	Reference	0.8
	Keratic precipitates	Yes	28/^*	1.59 (1.04 - 2.42)	0.03	23/^*	1.07 (0.64 - 1.77)	0.8
Structural complications	Any^†		164/^*	2.70 (1.99 - 3.65)	<.001	127/^*	1.58 (1.11 - 2.26)	0.01
	Band keratopathy		57/^*	9.71 (6.98 - 13.50)	<.001	38/^*	2.79 (1.57 - 4.94)	<.001
	Peripheral anterior synechia		12/^*	2.95 (1.62 - 5.39)	<.001	8/^*	1.29 (0.60 - 2.73)	0.51
	Posterior synechia		77/^*	2.68 (1.97 - 3.63)	<.001	52/^*	2.45 (1.66 - 3.61)	<.001
	Exudative detachment		13/^*	12.32 (6.54 - 23.21)	<.001	13/^*	4.84 (2.23 - 10.49)	<.001

^†

Any systemic disease includes those in the table as well as Behçet’s disease. Any structural complication includes those in the table as well as choroidal neovascularization, epiretinal membrane, exudative detachment, macular edema and retinal neovascularization

The number at risk for time-varying characteristics changes over followup, and is therefore not reported as a number of patients

^**

Adjusting for age, race, hypertension, juvenile idiopathic arthritis, systemic diseases^†, type of uveitis, presence of contralateral uveitis, duration of uveitis at presentation, prior cataract surgery by type, prior pars plana vitrectomy, prior retinal detachment surgery, anterior chamber cells and presence of exudative retinal detachment. However, ‡ Vitreous cells and haze are never adjusted by anterior chamber cells

^§

Hyperlipidemia, smoking status, epiretinal membrane, and macular edema were studied but are not included in the table because they were never found to be significant at p<0.10. Retinal vascular sheathing, presence of active lesions in choroid/retina, snowballs, snowbanking, Behçes Disease, choroidal neovascularization and retinal neovascularization are excluded from the table because eyes with these characteristics had fewer than 5 hypotony events, and there was no suggestion of a protective pattern.